SANUWAVE Health (SNWV) 10-Q 14 Aug 20 2020 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 12, 2020
Warrants [Text Block]
Entity Registrant Name	SANUWAVE Health, Inc.
Entity Central Index Key	0001417663
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	NV
Entity File Number	000-52985
Entity Common Stock, Shares Outstanding		302,119,428
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2020	Dec. 31, 2019
CURRENT ASSETS
Cash and cash equivalents	$ 430,606	$ 1,760,455
Accounts receivable, net of allowance for doubtful of $255,503 in 2020 and $72,376 in 2019	110,501	75,543
Inventory	651,344	542,955
Prepaid expenses and other current assets	1,337,086	125,405
TOTAL CURRENT ASSETS	2,529,537	2,504,358
PROPERTY AND EQUIPMENT, net	591,064	512,042
RIGHT OF USE ASSETS, net	243,251	323,661
OTHER ASSETS	43,096	41,931
TOTAL ASSETS	3,406,948	3,381,992
CURRENT LIABILITIES
Accounts payable	1,799,630	1,439,413
Accrued expenses	1,071,214	1,111,109
Accrued employee compensation	2,160,610	1,452,910
Contract liabilities	551,755	66,577
Operating lease liability	179,524	173,270
Finance lease liability	181,371	121,634
Convertible promissory notes, net	705,980	0
SBA loans	614,335	0
Line of credit, related parties	222,164	212,388
Short term note payable	210,000	587,233
Advances from related parties	0	18,098
Notes payable, related parties, net	5,372,743	5,372,743
Accrued interest, related parties	2,229,713	1,859,977
TOTAL CURRENT LIABILITIES	15,299,039	12,415,352
NON-CURRENT LIABILITIES
Contract liabilities	53,782	573,224
Operating lease liability	92,889	185,777
Finance lease liability	333,771	271,240
TOTAL NON-CURRENT LIABILITIES	480,442	1,030,241
TOTAL LIABILITIES	15,779,481	13,445,593
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
PREFERRED STOCK	0	0
COMMON STOCK, par value $0.001, 350,000,000 shares authorized; 302,119,428 and 293,780,400 issued and outstanding in 2020 and 2019, respectively	302,119	293,781
ADDITIONAL PAID-IN CAPITAL	117,326,629	115,457,808
ACCUMULATED DEFICIT	(132,386,958)	(125,752,956)
ACCUMULATED OTHER COMPREHENSIVE LOSS	(64,323)	(62,234)
TOTAL STOCKHOLDERS' DEFICIT	(14,822,533)	(10,063,601)
TOTAL LIABILITIES, MEZZANIE EQUITY AND STOCKHOLDERS' DEFICIT	3,406,948	3,381,992
Series C Convertible Preferred Stock
NON-CURRENT LIABILITIES
REDEEMABLE PREFERRED STOCK, SERIES C CONVERTIBLE, par value $0.001, 90 designated; 90 shares issued and outstanding in 2020	2,250,000	0
Series D Convertible Preferred Stock
NON-CURRENT LIABILITIES
REDEEMABLE PREFERRED STOCK, SERIES D CONVERTIBLE, par value $0.001, 8 designater; 8 shares issued and outstanding in 2020	200,000	0
Series A Convertible Preferred Stock
STOCKHOLDERS' DEFICIT
PREFERRED STOCK	0	0
Series B Convertible Preferred Stock
STOCKHOLDERS' DEFICIT
PREFERRED STOCK	$ 0	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Accounts receivable, allowance for doubtful accounts		$ 72,376
Preferred stock, par value	$ .001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ .001	$ 0.001
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	302,119,428	293,780,400
Common stock, shares outstanding	302,119,428	293,780,400
Series C Convertible Preferred Stock
Preferred stock, par value	$ .001	$ 0.001
Preferred stock, shares authorized	90	90
Preferred stock, shares issued	90	90
Preferred stock, shares outstanding	90	90
Series D Convertible Preferred Stock
Preferred stock, par value	$ .001	$ 0.001
Preferred stock, shares authorized	8	8
Preferred stock, shares issued	8	8
Preferred stock, shares outstanding	8	8
Series A Convertible Preferred Stock
Preferred stock, shares authorized	6,175	6,175
Series B Convertible Preferred Stock
Preferred stock, shares authorized	293	293

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
REVENUES	$ 83,301	$ 316,976	$ 231,893	$ 494,939
COST OF REVENUES	26,347	185,881	115,224	279,734
GROSS MARGIN	56,954	131,095	116,669	215,205
OPERATING EXPENSES
Research and development	264,907	307,273	551,661	567,922
Selling and marketing	433,151	407,477	1,041,001	565,559
General and administrative	2,566,793	1,426,405	4,474,710	2,943,860
Depreciation	64,766	9,455	117,789	17,812
TOTAL OPERATING EXPENSES	3,329,617	2,150,610	6,185,161	4,095,153
OPERATING LOSS	(3,272,663)	(2,019,515)	(6,068,492)	(3,879,948)
OTHER INCOME (EXPENSE)
Gain on warrant valuation adjustment	0	195,310	0	227,669
Interest expense	(168,941)	(790,178)	(187,673)	(938,439)
Interest expense, related party	(187,172)	(112,984)	(369,736)	(332,671)
Loss on foreign currency exchange	(4,244)	(7,064)	(8,267)	(8,359)
TOTAL OTHER INCOME (EXPENSE), NET	(360,357)	(714,916)	(565,676)	(1,051,800)
NET LOSS	(3,633,020)	(2,734,431)	(6,634,168)	(4,931,748)
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustments	(6,551)	1,489	(1,923)	(909)
TOTAL COMPREHENSIVE LOSS	$ (3,639,571)	$ (2,732,942)	$ (6,636,091)	$ (4,932,657)
LOSS PER SHARE:
Net loss - basic and diluted	$ (0.01)	$ (0.02)	$ (0.02)	$ (0.03)
Weighted average shares outstanding - basic and diluted	299,497,960	174,730,747	297,856,870	165,921,811
Product
REVENUES	$ 69,341	$ 220,667	$ 143,900	$ 285,232
COST OF REVENUES	24,825	178,458	103,740	243,570
License Fees
REVENUES	0	66,808	10,000	173,058
COST OF REVENUES			11,484	36,164
Other
REVENUES	13,960	29,501	77,993	36,649
COST OF REVENUES	$ 1,522	$ 7,423	$ 0	$ 0

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($)	Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Beginning balance (in shares) at Dec. 31, 2018	0	155,665,138
Beginning balance at Dec. 31, 2018	$ 0	$ 155,665	$ 101,153,882	$ (116,602,778)	$ 96,268	$ (15,356,099)
Net loss				(2,197,317)		(2,197,317)
Cashless warrant exercises (in shares)		704,108
Cashless warrant exercises		$ 704	(704)			0
Proceeds from warrant exercise (in shares)		620,000
Proceeds from warrant exercise		$ 620	52,580			53,200
Stock-based compensation						0
Conversion of short term notes and convertible notes payable (in shares)		3,333,334
Conversion of short term notes and convertible notes payable		$ 3,334	263,333			266,667
Conversion of advances from related parties						0
Reclassification of warrant liability to equity due to adoption of ASU 2017-11			262,339	1,279,661		1,542,000
Foreign currency translation adjustment					(2,398)	(2,398)
Ending balance (in shares) at Mar. 31, 2019	0	160,322,580
Ending balance at Mar. 31, 2019	$ 0	$ 160,323	101,731,430	(117,520,434)	(65,266)	(15,693,947)
Beginning balance (in shares) at Dec. 31, 2018	0	155,665,138
Beginning balance at Dec. 31, 2018	$ 0	$ 155,665	101,153,882	(116,602,778)	96,268	(15,356,099)
Net loss						(4,931,748)
Beneficial conversion feature on convertible debt						0
Conversion of advances from related parties						180,000
Ending balance (in shares) at Jun. 30, 2019	0	188,650,891
Ending balance at Jun. 30, 2019	$ 0	$ 188,651	103,774,485	(120,254,865)	(63,777)	(16,355,506)
Beginning balance (in shares) at Mar. 31, 2019	0	160,322,580
Beginning balance at Mar. 31, 2019	$ 0	$ 160,323	101,731,430	(117,520,434)	(65,266)	(15,693,947)
Net loss				(2,734,431)		(2,734,431)
Proceeds from stock option exercise, amount						31,758
Cashless warrant exercises (in shares)		2,997,375
Cashless warrant exercises		$ 2,997	13,003			16,000
Proceeds from warrant exercise (in shares)		17,051,769
Proceeds from warrant exercise		$ 17,052	1,333,005			1,350,057
Other warrant exercise, shares		5,804,167
Other warrant exercise, amount		$ 5,804	451,697			457,501
Stock-based compensation			31,758			31,758
Conversion of short term notes and convertible notes payable (in shares)		2,475,000
Conversion of short term notes and convertible notes payable		$ 2,475	177,525			180,000
Warrants issued for consulting services			36,067			36,067
Foreign currency translation adjustment					1,489	1,489
Ending balance (in shares) at Jun. 30, 2019	0	188,650,891
Ending balance at Jun. 30, 2019	$ 0	$ 188,651	103,774,485	(120,254,865)	(63,777)	(16,355,506)
Beginning balance (in shares) at Dec. 31, 2019	0	293,780,400
Beginning balance at Dec. 31, 2019	$ 0	$ 293,781	115,457,808	(125,752,956)	(62,234)	(10,063,601)
Net loss				(3,001,148)		(3,001,148)
Proceeds from warrant exercise (in shares)		1,000,000
Proceeds from warrant exercise		$ 1,000	9,000			10,000
Shares issued for services (in shares)		1,000,000
Shares issued for services		$ 1,000	199,000			200,000
Stock-based compensation			21,900			21,900
Conversion of short term notes and convertible notes payable (in shares)		1,820,461
Conversion of short term notes and convertible notes payable		$ 1,820	262,164			263,984
Conversion of advances from related parties (in shares)		62,811
Conversion of advances from related parties		$ 63	2,035			2,098
Foreign currency translation adjustment					4,826	4,826
Ending balance (in shares) at Mar. 31, 2020	0	297,663,672
Ending balance at Mar. 31, 2020	$ 0	$ 297,664	115,951,907	(128,754,104)	(57,408)	(12,561,941)
Beginning balance (in shares) at Dec. 31, 2019	0	293,780,400
Beginning balance at Dec. 31, 2019	$ 0	$ 293,781	115,457,808	(125,752,956)	(62,234)	(10,063,601)
Net loss						(6,634,002)
Beneficial conversion feature on convertible debt						560,682
Conversion of short term notes and convertible notes payable						354,729
Conversion of advances from related parties						18,098
Ending balance (in shares) at Jun. 30, 2020	0	302,119,428
Ending balance at Jun. 30, 2020	$ 0	$ 302,119	117,326,629	(132,386,958)	(64,323)	(14,822,533)
Beginning balance (in shares) at Mar. 31, 2020	0	297,663,672
Beginning balance at Mar. 31, 2020	$ 0	$ 297,664	115,951,907	(128,754,104)	(57,408)	(12,561,941)
Net loss				(3,632,854)		(3,632,854)
Proceeds from PIPE, shares		1,071,428
Proceeds from PIPE, amount		$ 1,071	1,489,929			150,000
Proceeds from stock option exercise, shares		225,000
Proceeds from stock option exercise, amount		$ 225	44,025			44,250
Beneficial conversion feature on convertible debt			560,682			560,682
Shares issued for services (in shares)		2,200,000
Shares issued for services		$ 2,200	515,300			517,500
Conversion of short term notes and convertible notes payable (in shares)		759,328
Conversion of short term notes and convertible notes payable		$ 759	89,986			90,745
Conversion of advances from related parties (in shares)		200,000
Conversion of advances from related parties		$ 200	15,800			16,000
Foreign currency translation adjustment					(6,915)	(6,915)
Ending balance (in shares) at Jun. 30, 2020	0	302,119,428
Ending balance at Jun. 30, 2020	$ 0	$ 302,119	$ 117,326,629	$ (132,386,958)	$ (64,323)	$ (14,822,533)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (6,634,002)	$ (4,931,748)
Adjustments to reconcile net loss to net cash used by operating activities
Depreciation	117,789	17,812
Change in allowance for doubtful accounts	183,127	25,248
Share-based payment	739,400	67,825
Amortization of debt issuance costs	69,862	0
Accrued interest	84,072	936,658
Interest payable, related parties	369,736	332,671
Amortization of operating leases	(6,224)	(3,471)
Waived proceeds from warrant exercise	0	16,000
Gain on warrant valuation adjustment	0	(227,669)
Changes in operating assets and liabilities
Accounts receivable - trade	(218,085)	34,485
Inventory	(108,389)	(66,112)
Prepaid expenses	(1,211,681)	(126,505)
Due from related parties	0	1,228
Other assets	(1,165)	(7,070)
Operating leases	0	44,623
Accounts payable	360,217	(135,916)
Accrued expenses	(39,895)	106,178
Accrued employee compensation	707,700	525,487
Contract liabilties	(34,264)	3,642
NET CASH USED BY OPERATING ACTIVITIES	(5,621,802)	(3,386,634)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(4,855)	(25,839)
NET CASH USED BY INVESTING ACTIVITIES	(4,855)	(25,839)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of convertible preferred stock	2,450,000	0
Proceeds from convertible promissory note	1,100,000	0
Proceeds from SBA loan	614,335	0
Proceeds from PIPE offering	150,000	0
Proceeds from stock option exercise	44,250	0
Proceeds from short term note	0	1,215,000
Proceeds from warrant exercise	10,000	1,403,257
Advances from related parties	0	585,022
Payments of principal on finance leases	(69,688)	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	4,298,897	3,203,279
EFFECT OF EXCHANGE RATES ON CASH	(2,089)	(909)
NET DECREASE IN CASH AND CASH EQUIVALENTS	(1,329,849)	(210,103)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	1,760,455	364,549
CASH AND CASH EQUIVALENTS, END OF PERIOD	430,606	154,446
NONCASH INVESTING ACTIVITIES
Conversion of short term notes payable to equity	354,729	724,168
Conversion of advances from related parties to equity	18,098	180,000
Additions to right of use assets from new finance lease liabilities	127,611	0
Beneficial conversion feature on convertible debt	560,682	0
Reclassification of warrant liability to equity	$ 0	$ 262,339

Note 1 - Nature of the Business

Note 1 - Nature of the Business	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business	SANUWAVE Health, Inc. and Subsidiaries (the “Company”) is a shock wave technology company using a patented system of noninvasive, high-energy, acoustic shock waves for regenerative medicine and other applications. The Company’s initial focus is regenerative medicine – utilizing noninvasive, acoustic shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal and vascular structures. The Company’s lead regenerative product in the United States is the dermaPACE® device, used for treating diabetic foot ulcers, which was subject to two double-blinded, randomized Phase III clinical studies. On December 28, 2017, the U.S. FDA granted the Company’s request to classify the dermaPACE System as a Class II device via the de novo The Company’s portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body’s normal healing processes and regeneration. The Company is marketing its dermaPACE System for treatment usage in the United States and is able to generate revenue from sales of the European Conformity Marking (CE Mark) devices and accessories in Europe, Canada, Asia, and Asia/Pacific. The Company generates revenue streams from dermaPACE treatments, product sales, licensing transactions and other activities. In March 2020, the World Health Organization characterized COVID-19 as a pandemic and the President of the United States declared the COVID-19 outbreak a national emergency. Since then, the COVID-19 pandemic has rapidly spread across the globe and has already resulted in significant volatility, uncertainty and economic disruption. While the COVID-19 pandemic has not had a material adverse financial impact on the Company’s operations to date, the future impacts of the pandemic and any resulting economic impact are largely unknown and rapidly evolving. It is difficult at this time to predict the impact that COVID-19 will have on the Company’s business, financial position and operating results in future periods due to numerous uncertainties. The Company is closely monitoring the impact of the pandemic on all aspects of its business and operations. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all the information and footnotes required by U.S. GAAP for complete financial statements. The financial information as of June 30, 2020 and for the three and six months ended June 30, 2020 and 2019 is unaudited; however, in the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for any other interim period or for the year ending December 31, 2020. The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These financial statements should be read in conjunction with the Company’s Form 10-K filed with the Securities and Exchange Commission on March 30, 2020 (the “2019 Annual Report”).

Note 2 - Going Concern

Note 2 - Going Concern	6 Months Ended
	Jun. 30, 2020
Notes Payable, Related Parties [Member]
Going Concern	The Company does not currently generate significant recurring revenue and will require additional capital during 2020. As of June 30, 2020, the Company had cash and cash equivalents of $430,606. For the six months ended June 30, 2020, the net cash used by operating activities was $5,621,968. The Company incurred a net loss of $6,634,168 for the six months ended June 30, 2020. The operating losses and the events of default on the Company’s short term notes payable (see Note 6) and the notes payable, related parties (see Note 9) raised substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the filing of this report. The continuation of the Company’s business is dependent upon raising additional capital to fund operations. Management’s plans are to obtain additional capital through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing arrangements, or raise capital through the issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt. These possibilities, to the extent available, may be on terms that result in significant dilution to the Company’s existing shareholders. Although no assurances can be given, management of the Company believes that potential additional issuances of equity or other potential financing transactions as discussed above should provide the necessary funding for the Company to continue as a going concern. If these efforts are unsuccessful, the Company may be forced to seek relief through a filing under the U.S. Bankruptcy Code. The condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	The significant accounting policies followed by the Company are summarized below and should be read in conjunction with the 2019 Annual Report: Principles of consolidation Estimates Inventory Preferred stock Distinguishing Liabilities from Equity Sequencing policy

Note 4 - Accrued Expenses

Note 4 - Accrued Expenses	6 Months Ended
	Jun. 30, 2020
Payables and Accruals [Abstract]
Accrued Expenses	Accrued expenses consist of the following: June 30, 2020 December 31, 2019 Accrued board of director's fees $ 416,667 $ 400,000 Accrued legal and professional fees 200,000 134,970 Accrued executive severance 163,000 154,000 Accrued travel 120,000 120,000 Accrued outside services 106,233 108,033 Accrued inventory 50,275 167,050 Accrued clinical study expenses 13,650 13,650 Accrued other 1,389 13,406 $ 1,071,214 $ 1,111,109

Note 5 - Contract Liabilities

Note 5 - Contract Liabilities	6 Months Ended
	Jun. 30, 2020
Contract with Customer, Liability [Abstract]
Contract liabilities	As of June 30, 2020, the Company has contract assets and liabilities from contracts with customers (see Note 14). Contract liabilities consist of the following: June 30, 2020 December 31, 2019 Service agreement $ 91,746 $ 133,510 License fees 500,000 500,000 Other 13,791 6,291 Total Contract liabilities 605,537 639,801 Non-Current (551,755 ) (573,224 ) Total Current $ 53,782 $ 66,577 The timing of the Company’s revenue recognition may differ from the timing of payment by its customers. A receivable is recorded when revenue is recognized prior to payment and the Company has an unconditional right to payment. Alternatively, when payment precedes the satisfaction of performance obligations, the Company records a contract liability (deferred revenue) until the performance obligations are satisfied. Of the aggregate contract liability balances as of June 30, 2020, the Company expects to satisfy its remaining performance obligations associated with $551,755 and $53,782 of contract liability balances within the next twelve months and following thirty-two months, respectively. Of the aggregate contract liability balances as of December 31, 2019, the Company expects to satisfy its remaining performance obligations associated with $66,577 and $573,224 of contract liability balances within the next twelve months and following thirty-eight months, respectively.

Note 6 - Short Term Notes Payab

Note 6 - Short Term Notes Payable	6 Months Ended
	Jun. 30, 2020
Notes Payable [Abstract]
Short Term Notes Payable	During the six months ended June 30, 2020, the Company converted $354,729 of the short-term notes payable into 2,579,789 shares of Company common stock, $0.001 par value (the “Common Stock”).

Note 7 - Convertible Promissory

Note 7 - Convertible Promissory Note	6 Months Ended
	Jun. 30, 2020
Convertible Notes Payable [Abstract]
Convertible Promissory Note	On June 5, 2020, the Company entered into a Securities Purchase Agreement with investor LGH Investments LLC (the “Investor”) for (i) a Promissory Note (the “Convertible Promissory Note”) in the original principal amount of $1,210,000, convertible into shares of Common Stock, (ii) warrants entitling the Investor to acquire 1,000,000 shares of Common Stock (the “Warrants”) and (iii) two hundred thousand (200,000) restricted common shares in the Company as an inducement grant (the “Inducement Shares”). The Convertible Promissory Note matures on February 5, 2021 and includes a one-time interest charge of 8% to be applied on the issuance date to the original principal amount. The Investor can convert the Convertible Promissory Note at any time prior to maturity to the number of shares of Common Stock, equal to the amount obtained by dividing (i) the amount of the unpaid principal and interest on the note by (ii) $0.25. The Warrants have an exercise price of $0.35 per share and have a term of five years. With respect to the Inducement Shares, in the event the Company’s share price has declined on the date on which the Investor seeks to have the restricted legend removed on such shares, the Company agrees to issue the Investor additional shares such that the aggregate value of the Inducement Shares equals the aggregate value of the Inducement Shares as of June 5, 2020. The Company recorded $381,013 debt discount for the beneficial conversion feature of the Convertible Promissory Note, $179,669 in debt discount for the discount on the Warrants and $110,000 in original issuance discount costs to be amortized over the lives of the Convertible Promissory Note. The Convertible Promissory Note had an aggregate outstanding principal balance of $705,980, net of $600,820 beneficial conversion feature, warrant discount and original issuance discount costs at June 30, 2020. Interest expense on the Convertible Promissory Note totaled $166,663 for the six months ended June 30, 2020.

Note 8 - SBA Loans

Note 8 - SBA Loans	6 Months Ended
	Jun. 30, 2020
Loans Payable [Abstract]
SBA Loans	On May 28, 2020, the Company received proceeds from a loan in the amount of $454,335 (the “PPP Loan”) from Truist Bank, as lender, pursuant to the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (15 U.S.C. 636(a)(36)) (the “CARES Act”). The PPP Loan matures on May 28, 2022 and bears interest at a rate of 1% per annum. Commencing December 12, 2020, the Company is required to pay the lender equal monthly payments of principal and interest. The PPP Loan is evidenced by a promissory note dated May 28, 2020 (the “Note”), which contains customary events of default relating to, among other things, payment defaults and breaches of representations, warranties and covenants. The PPP Loan may be prepaid by the Company at any time prior to maturity with no prepayment penalties. All or a portion of the PPP Loan may be forgiven by the U.S. Small Business Administration (“SBA”) upon application by the Company beginning 60 days but not later than 120 days after loan approval and upon documentation of expenditures in accordance with the SBA requirements. Under the terms of the PPP Loan, the Company may be eligible for full or partial loan forgiveness in the third quarter of 2020, however, no assurance is provided that the Company will apply for, or obtain forgiveness for, any portion of the PPP Loan. On June 10, 2020, the Company secured a loan offered by the U.S. Small Business Administration (SBA) under its Economic Injury Disaster Loan (“EIDL”) assistance program in light of the impact of COVID-19 pandemic on the Company’s business. The principal amount of this loan of $150,000 with proceeds to be used for working capital purposes. Interest accrues at the rate of 3.75% per annum. Installment payments, including principal and interest, are due monthly beginning June 10, 2021. The balance of principal and interest is payable 30 years from the date of the EIDL. The EIDL is secured by a security interest on all of the Company’s assets.

Note 9 - Notes Payable, Related

Note 9 - Notes Payable, Related Parties	6 Months Ended
	Jun. 30, 2020
Notes Payable [Abstract]
Notes Payable, Related Parties	The notes payable, related parties as amended were issued in conjunction with the Company’s purchase of the orthopedic division of HealthTronics, Inc. The notes payable, related parties bear interest at 8% per annum, as amended. All remaining unpaid accrued interest and principal was due on December 31, 2018, as amended. HealthTronics, Inc. is a related party because it is a shareholder in the Company and has a security agreement with the Company detailed below. The Company is a party to a security agreement with HealthTronics, Inc. to provide a first security interest in the assets of the Company. During any period when an Event of Default occurs, the applicable interest rate shall increase by 2% per annum. An Event of Default under the notes payable, related parties occurred on December 31, 2016 (“Default”). As a result of the Default, the notes payable, related parties have been accruing interest at the rate of 10% per annum since January 2, 2017 and continue to accrue interest at such rate. The Company will be required to make mandatory prepayments of principal on the notes payable, related parties equal to 20% of the proceeds received by the Company through the issuance or sale of any equity securities in cash or through the licensing of the Company’s patents or other intellectual property rights. For the three months ended June 30, 2020, additional mandatory prepayments of principal and interest on the notes payable, related parties were due on June 30, 2020. The Company has not made the mandatory prepayments of principal to HealthTronics, Inc. on the notes payable, related parties as amended from proceeds received through the issuance or sale of any equity securities in cash through June 30, 2020. The notes payable, related parties had an aggregate outstanding principal balance of $5,372,743 at June 30, 2020 and December 31, 2019. Accrued interest, related parties currently payable totaled $2,229,713 at June 30, 2020 and $1,859,977 at December 31, 2019. Interest expense on notes payable, related parties totaled $187,172 and $112,984 for the three months ended June 30, 2020 and 2019, respectively and $369,736 and $332,671 for the six months ended June 30, 2020 and 2019, respectively. As of June 30, 2020, we are in default under the notes, as amended, and as a result HealthTronics, Inc. could, among other rights and remedies, exercise its rights under its first priority security interest in our assets. We are in negotiations with HealthTronics, Inc. to address the event of default.

Note 10 - Preferred Stock

Note 10 - Preferred Stock	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Preferred Stock	On February 6, 2020, the Company entered into a Series C Preferred Stock Purchase Agreement (the “Series C Purchase Agreement”) with certain accredited investors for the sale by the Company in a private placement of an aggregate of 90 shares of the Company’s Series C Convertible Preferred Stock, par value $0.001 per share at a stated value equal to $25,000 per share (the “Series C Preferred Stock”), for an aggregate total purchase price of $2,250,000. On January 31, 2020, the Company filed a Certificate of Designation of Preferences, Right and Limitations of Series C Convertible Preferred Stock of the Company with the Nevada Secretary of State which amended our Articles of Incorporation to designate 90 shares of our preferred stock as Series C Convertible Preferred Stock. On May 14, 2020, the Company entered into a Series D Preferred Stock Purchase Agreement (the “Series D Purchase Agreement”) with certain accredited investors for the sale by the Company in a private placement of an aggregate of eight shares of the Company’s Series D Convertible Preferred Stock, par value $0.001 per share at a stated value equal to $25,000 per share (the “Series D Preferred Stock”), for an aggregate total purchase price of $200,000. On May 14, 2020, the Company filed a Certificate of Designation of Preferences, Right and Limitations of Series D Convertible Preferred Stock of the Company with the Nevada Secretary of State which amended our Articles of Incorporation to designate eight shares of our preferred stock as Series D Convertible Preferred Stock. Subject to the terms of the Certificates of Designation, each share of Series C Preferred Stock and Series D Preferred Stock is convertible into shares of Common Stock of the Company at a rate equal to the stated value of such share of Series C Preferred Stock and Series D Preferred Stock of $25,000, divided by the conversion price of $0.14 per share (subject to adjustment from time to time upon the occurrence of certain events as described in the Certificate of Designation). The Certificates of Designation became effective upon filing with the Secretary of State of the State of Nevada. If all outstanding shares of Series C Preferred Stock and Series D Preferred Stock were converted into Common Stock at the original conversion rate, such shares would convert into an aggregate of 17,500,000 shares of Common Stock. Notwithstanding the foregoing, the Series C Preferred Stock and Series D Preferred Stock is not currently convertible into shares of Common Stock because the Company does not currently have sufficient authorized and unissued shares of its Common Stock to permit conversion in full of all issued and outstanding shares of Series C Preferred Stock and Series D Preferred Stock. Accordingly, the Certificate of Designation provides that the Series C Preferred Stock and Series D Preferred Stock is only convertible into Common Stock once the Company amends its Articles of Incorporation to increase its authorized and unissued Common Stock to an amount sufficient to permit such conversion of the Series C Preferred Stock and Series D Preferred Stock. Each investor has agreed in the Purchase Agreement that such investor will, within five business days following such amendment to the Articles of Incorporation, convert all of such investor’s shares of Series C Preferred Stock and Series D Preferred Stock into shares of Common Stock. The Certificate of Designation provides that if the Company has not obtained the approval of its shareholders to amend the Company’s Articles of Incorporation to increase the authorized shares of Common Stock sufficient to permit such conversion, or if such amendment has not otherwise been filed with the Nevada Secretary of State on or before December 31, 2020 (either such event, an “Authorization Failure”), then the Company shall be required to redeem all outstanding shares of Series C Preferred Stock and Series D Preferred Stock for a per-share redemption price, payable in cash in a single installment not later than thirty (30) days following the date of such Authorization Failure, equal to the greater of (a) two hundred percent (200%) of the stated value of such share, and (b)(i) the volume-weighted average sale price of a share of Common Stock reported on the trading market on which the Common Stock is then traded for the thirty (30) consecutive trading days immediately preceding the date of such Authorization Failure, multiplied by (ii) the number of shares of Common Stock such share of Series C Preferred Stock and Series D Preferred Stock would otherwise be convertible into as of such date had such Authorization Failure not occurred. The closing of the private placements occurred on February 6, 2020 and May 14, 2020, respectively, and the preferred stock was recorded in temporary equity on the related condensed consolidated balance sheet at an aggregate value of $2,250,000 and $200,000 respectively. Ninety shares of the Series C Preferred Stock and eight shares of Series D Preferred Stock have been issued as of June 30, 2020.

Note 11 - Equity Transactions

Note 11 - Equity Transactions	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Equity Transactions	Warrant Exercises During the six months ended June 30, 2020, the Company issued 1,000,000 shares of Common Stock upon the exercise of 1,000,000 Class P Warrants to purchase shares of stock and an exercise price of $0.01 per share under the terms of the respective warrant agreement. Conversion of liabilities During the six months ended June 30, 2020, the Company issued 2,579,789 shares of Common Stock upon the conversion of short term notes payable in the principal and accrued interest amount of $354,729 with the receipt of notices of Class L warrant exercises, all pursuant to the terms of the short term notes payable. Conversion of advances from related parties During the six months ended June 30, 2020, the Company issued 262,811 shares of Common Stock upon the conversion of advances from related parties in the amount of $18,098 with the receipt of notice of Series A Warrant exercise to purchase shares of stock under the terms of the respective warrant agreement. Consulting Agreement In January 2020, the Company entered into a six month consulting agreement for which the fee for the services was to be paid with Common Stock. The number of shares to be paid with Common Stock was 1,000,000 earned upon signing and an additional 1,000,000 upon agreement by both consultant and the Company no later than May 1, 2020. The Company issued 1,000,000 shares in March 2020 and 1,000,000 shares in April 2020. The fair value of the shares of $380,000 was recorded as a non-cash general and administrative expense during the six months ended June 30, 2020. The consulting agreement was extended to November 30, 2020 with an additional 2,000,000 Common Stock shares to be issued for services. The Company issued 1,000,000 shares to the consultant in June 2020. The fair value of the shares of $287,500 was recorded as a non-cash general and administrative expense during the six months ended June 30, 2020. PIPE Offering On December 11, 2019, the Company entered into a Common Stock Purchase Agreement with certain investors for the sale by the Company in a private placement of an aggregate of up to 21,071,143 shares of its common stock at a purchase price of $0.14 per share. During the six months ended June 30, 2020, the Company issued 1,071,428 shares of Common Stock in conjunction with this offering and received $150,000 in cash proceeds. Stock Option Exercise During the six months ended June 30, 2020, the Company issued 225,000 shares of Common Stock upon the exercise of stock options to purchase shares of common stock, resulting in net proceeds of $44,250. Litigation Settlement During the six months ended June 30, 2020, the Company issued 200,000 shares of restricted Common Stock upon the settlement of outstanding litigation. The fair value of the shares of $50,000 was recorded as a non-cash general and administrative expense during the six months ended June 30, 2020.

Note 12 - Warrants

Note 12 - Warrants	6 Months Ended
	Jun. 30, 2020
Note 12 - Warrants
Warrants	A summary of the warrant activity during the six months ended June 30, 2020 is presented as follows: Warrant class Outstanding as of December 31, 2019 Issued Exercised Expired Outstanding as of June 30, 2020 Class K Warrants 7,200,000 - - - 7,200,000 Class O Warrants 909,091 - - - 909,091 Class P Warrants 1,365,000 - (1,000,000 ) (100,000 ) 265,000 Common Stock Purchase Warrants - 1,000,000 - - 1,000,000 9,474,091 1,000,000 (1,000,000 ) (100,000 ) 9,374,091 A summary of the warrant exercise price per share and expiration date is presented as follows: Exercise price/share Expiration date Class K Warrants $ 0.08 June 2025 Class K Warrants $ 0.11 August 2027 Class O Warrants $ 0.11 January2022 Class P Warrants $ 0.20 June 2024 Common Stock Purchase Warrants $ 0.35 June 2025

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Operating Leases The Company is a party to certain operating leases. The Company has entered into a lease agreement, as amended, for office space for office, research and development, quality control, production and warehouse space which expires on December 31, 2021. Under the terms of the lease, the Company pays monthly rent of $14,651, subject to a 3% adjustment on an annual basis. For leases where the Company is the lessee, ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date (except we used the practical expedients and recorded the outstanding operating lease at January 1, 2019) based on the present value of lease payments over the lease term. As the Company’s lease did not provide an implicit interest rate, the Company used the equivalent borrowing rate for a secured financing with the term of that equal to the remaining life of the lease at inception. The lease terms used to calculate the ROU asset and related lease liability did not include options to extend or termination of the lease; there are none and there is no reasonable certainty that the Company would extend the lease at expiration. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense. The Company has lease agreements which require payments for lease and non-lease components and has elected to account for these as separate lease components. Non-leasing components are not included in the ROU asset. Right of use assets and Lease liability – right of use consist of the following: June 30, 2020 Right of use assets $ 243,251 June 30, 2020 Lease liability - right of use Current portion $ 173,270 Long term portion 99,142 $ 272,412 As of June 30, 2020, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following: Year ending December 31, Amount 2020 (remainder) $ 97,041 2021 197,462 Total lease payments 294,503 Less: Present value adjustment (22,090 ) Lease liability - right of use $ 272,413 As of June 30, 2020, the Company’s operating lease had a weighted average remaining lease term of 1.5 years and a weighted average discount rate of 7%. Rent expense for the three months ended June 30, 2020 and 2019 was $52,346 and $54,698, respectively, and for the six months ended June 30, 2020 and 2019 was $117,876 and $107,536, respectively. Financing Lease For leases where the Company is the lessee, ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The present value of the lease payment exceeds 90% of the sales price of the equipment, therefore this lease will be considered a financing lease is included in Property and equipment, net on our Condensed Consolidated Balance Sheets. Lease expense will be recognized as payment of financing lease, depreciation expense and interest expense. Right of use assets and Lease liability – right of use consist of the following: June 30, 2020 Right of use assets $ 515,551 June 30, 2020 Lease liability - right of use Current portion $ 181,371 Long term portion 333,771 $ 515,141 As of June 30, 2020, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following: Year ending December 31, Amount 2020 (remainder) $ 117,297 2021 234,593 2022 199,793 2023 18,388 Total $ 570,071 As of June 30, 2020, the Company’s financing leases had a weighted average remaining lease term of 2.44 years based on annualized base payments expiring through 2023 and a weighted average discount rate of 13.2%. As of June 30, 2020, the Company did not have additional operating or financing leases that have yet commenced. Litigation From time to time, the Company is subject to various legal actions, claims and proceedings arising in the ordinary course of business, including claims related to breach of contracts and intellectual property matters resulting from our business activities. As with most actions such as these, an estimation of any possible and/or ultimate liability cannot always be determined. We believe that all pending claims, if adversely decided, would not have a material adverse effect on our business, financial position or results of operations.

Note 14 - Revenue

Note 14 - Revenue	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue	The Company accounts for revenue in accordance with ASC 606. Disaggregation of Revenue The disaggregation of revenue is based on geographical region. The following table presents revenue from contracts with customers for the three and six months ended June 30, 2020 and 2019: Three months ended June 30, 2020 Three months ended June 30, 2019 United States International Total United States International Total Product $ 63,076 $ 6,265 $ 69,341 $ 120,488 $ 100,179 $ 220,667 License fees - - - 6,250 60,558 66,808 Other Revenue 711 13,249 13,960 - 29,501 29,501 $ 63,787 $ 19,514 $ 83,301 $ 126,738 $ 190,238 $ 316,976 Six months ended June 30, 2020 Six months ended June 30, 2019 United States International Total United States International Total Product $ 96,730 $ 47,170 $ 143,900 $ 138,167 $ 147,065 $ 285,232 License fees 10,000 - 10,000 12,500 160,558 173,058 Other Revenue 1,252 76,741 77,993 - 36,649 36,649 $ 107,982 $ 123,911 $ 231,893 $ 150,667 $ 344,272 $ 494,939 Management routinely assesses the financial strength of its customers and, as a consequence, believes accounts receivable are stated at the net realizable value and credit risk exposure is limited. One distributor accounted for 86% of revenue for the six months ended June 30, 2020 and 72% of accounts receivable at June 30, 2020. Three distributors accounted for 72% of revenues for the six months ended June 30, 2019 and 49%, 0% and 25% of accounts receivable at June 30, 2019.

Note 15 - Related Party Transa

Note 15 - Related Party Transactions	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	During the three and six months ended June 30, 2020 and 2019, the Company recorded $13,105 and $17,678, respectively, and $26,210 and $138,167 respectively, in revenue from an entity owned by A. Michael Stolarski, a member of the Company’s board of directors and an existing shareholder of the Company. Contract liabilities includes a balance at June 30, 2020 and 2019 of $90,943 and $102,899, respectively from this related party.

Note 16 - Stock-based Compensat

Note 16 - Stock-based Compensation	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement, Noncash Expense [Abstract]
Stock-based Compensation	During the six months ended June 30, 2020, 10,000 stock options to purchase the Company’s common stock were forfeited due to termination. The range of exercise prices for options was $0.04 to $2.00 for options outstanding at June 30, 2020 and December 31, 2019, respectively. The aggregate intrinsic value for all vested and exercisable options was $3,034,841 and $2,085,866 at June 30, 2020 and December 31, 2019, respectively. The weighted average remaining contractual term for outstanding exercisable stock options was 6.1 and 6.6 years as of June 30, 2020 and December 31, 2019, respectively.

Note 17 - Earnings (Loss) Per S

Note 17 - Earnings (Loss) Per Share	6 Months Ended
	Jun. 30, 2020
LOSS PER SHARE:
Earnings (Loss) Per Share	Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. Potentially dilutive securities are excluded from the computation of diluted net loss per share as their inclusive would be anti-dilutive and consist of the following: June 30, 2020 June 30, 2019 Stock options 34,168,385 32,183,385 Preferred stock conversion 17,500,000 - Warrants 9,374,091 68,357,635 Convertible promissory notes 5,227,200 26,004,347 Short term notes payable 2,250,000 - Anti-dilutive equity securities 68,519,676 126,545,367

Note 18 - Subsequent Events

Note 18 - Subsequent Events	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	On July 23, 2020, in connection with the Company’s 2020 Annual Meeting of Stockholders, the Company’s stockholders approved, among other matters, the following; ● An amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of Common Stock from 355,000,000 to 605,000,000; and ● To grant the board of directors the authority to effect a reverse split of the Company’s outstanding Common Stock at an exchange rate of between 1-for-10 and 1-for-50, with the exact ratio to be determined by the board of directors in its sole discretion. Amendments to the Company’s Articles of Incorporation to effect the increase in the number of authorized shares of Common Stock and the reverse stock split have not yet been filed with the Secretary of State of Nevada. [ PLACEHOLDER FOR CELULARITY The Company has evaluated its subsequent events from June 30, 2020 through the date these condensed consolidated financial statements were issued, and has determined that there are no additional subsequent events required to be disclosed.

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Principles of Consolidation	The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Estimates	These condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. Because a precise determination of assets and liabilities, and correspondingly revenues and expenses, depend on future events, the preparation of condensed consolidated financial statements for any period necessarily involves the use of estimates and assumptions. Actual amounts may differ from these estimates. These condensed consolidated financial statements have, in management’s opinion, been properly prepared within reasonable limits of materiality and within the framework of the accounting policies summarized herein. Significant estimates include the recording of allowances for doubtful accounts, estimate of the net realizable value of inventory, the determination of the valuation allowances for deferred taxes, estimated fair value of stock-based compensation, and debt discounts of warrants.
Inventory	Inventory consists of finished medical equipment and parts and is stated at the lower of cost, which is valued using the first in, first out (“FIFO”) method, or net realizable value less allowance for selling and distribution expenses. The Company analyzes its inventory levels and writes down inventory that has, or is expected to, become obsolete. As of June 30, 2020, inventory consists of goods of $367,988 and parts of $283,356 for a total inventory of $651,344. As of December 31, 2019, inventory consisted of goods of $357,264 and parts of $185,691 for a total inventory of $542,955.
Preferred Stock	The Company evaluates Preferred Stock issuances for liability or equity classification in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity
Sequencing policy	The Company has granted certain options and warrants which, upon settlement, may exceed the limit on the authorized number of shares of common stock. The Company follows a sequencing policy for which in the event partial reclassifications of contracts subject to ASC 815-40-25 is necessary, due to the Company’s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of earliest issuance date of potentially dilutive instruments with the earliest grants receiving first allocation of shares. The Company evaluated such instruments and determined that there was no impact to the Company’s condensed consolidated financial statements.

Note 4 - Accrued Expenses (Tabl

Note 4 - Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2020
Payables and Accruals [Abstract]
Accrued expenses	June 30, 2020 December 31, 2019 Accrued board of director's fees $ 416,667 $ 400,000 Accrued legal and professional fees 200,000 134,970 Accrued executive severance 163,000 154,000 Accrued travel 120,000 120,000 Accrued outside services 106,233 108,033 Accrued inventory 50,275 167,050 Accrued clinical study expenses 13,650 13,650 Accrued other 1,389 13,406 $ 1,071,214 $ 1,111,109

Note 5 - Contract Liabilities (

Note 5 - Contract Liabilities (Tables)	6 Months Ended
	Jun. 30, 2020
Contract with Customer, Liability [Abstract]
Contract liabilities	June 30, 2020 December 31, 2019 Service agreement $ 91,746 $ 133,510 License fees 500,000 500,000 Other 13,791 6,291 Total Contract liabilities 605,537 639,801 Non-Current (551,755 ) (573,224 ) Total Current $ 53,782 $ 66,577

Note 12 - Warrants (Tables)

Note 12 - Warrants (Tables)	6 Months Ended
	Jun. 30, 2020
Note 12 - Warrants
Warrant activity	Warrant class Outstanding as of December 31, 2019 Issued Exercised Expired Outstanding as of June 30, 2020 Class K Warrants 7,200,000 - - - 7,200,000 Class O Warrants 909,091 - - - 909,091 Class P Warrants 1,365,000 - (1,000,000 ) (100,000 ) 265,000 Common Stock Purchase Warrants - 1,000,000 - - 1,000,000 9,474,091 1,000,000 (1,000,000 ) (100,000 ) 9,374,091
Warrant exercise price per share	Exercise price/share Expiration date Class K Warrants $ 0.08 June 2025 Class K Warrants $ 0.11 August 2027 Class O Warrants $ 0.11 January2022 Class P Warrants $ 0.20 June 2024 Common Stock Purchase Warrants $ 0.35 June 2025

Note 13 - Commitments and Con_2

Note 13 - Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Operating right of use assets and lease liabilities	June 30, 2020 Right of use assets $ 243,251 June 30, 2020 Lease liability - right of use Current portion $ 173,270 Long term portion 99,142 $ 272,412
Operating lease liability maturities	Year ending December 31, Amount 2020 (remainder) $ 97,041 2021 197,462 Total lease payments 294,503 Less: Present value adjustment (22,090 ) Lease liability - right of use $ 272,413
Finance right of use assets and lease liabilities	June 30, 2020 Right of use assets $ 515,551 June 30, 2020 Lease liability - right of use Current portion $ 181,371 Long term portion 333,771 $ 515,141
Finance lease liability maturities	Year ending December 31, Amount 2020 (remainder) $ 117,297 2021 234,593 2022 199,793 2023 18,388 Total $ 570,071

Note 14 - Revenue (Tables)

Note 14 - Revenue (Tables)	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of revenue	Three months ended June 30, 2020 Three months ended June 30, 2019 United States International Total United States International Total Product $ 63,076 $ 6,265 $ 69,341 $ 120,488 $ 100,179 $ 220,667 License fees - - - 6,250 60,558 66,808 Other Revenue 711 13,249 13,960 - 29,501 29,501 $ 63,787 $ 19,514 $ 83,301 $ 126,738 $ 190,238 $ 316,976 Six months ended June 30, 2020 Six months ended June 30, 2019 United States International Total United States International Total Product $ 96,730 $ 47,170 $ 143,900 $ 138,167 $ 147,065 $ 285,232 License fees 10,000 - 10,000 12,500 160,558 173,058 Other Revenue 1,252 76,741 77,993 - 36,649 36,649 $ 107,982 $ 123,911 $ 231,893 $ 150,667 $ 344,272 $ 494,939

Note 17 - Earnings (Loss) Per_2

Note 17 - Earnings (Loss) Per Share (Tables)	6 Months Ended
	Jun. 30, 2020
LOSS PER SHARE:
Antidilutive shares	June 30, 2020 June 30, 2019 Stock options 34,168,385 32,183,385 Preferred stock conversion 17,500,000 - Warrants 9,374,091 68,357,635 Convertible promissory notes 5,227,200 26,004,347 Short term notes payable 2,250,000 - Anti-dilutive equity securities 68,519,676 126,545,367

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Notes Payable, Related Parties [Member]
Accumulated deficit	$ (132,386,958)		$ (132,386,958)		$ (125,752,956)
Cash and cash equivalents	430,606	$ 154,446	430,606	$ 154,446	$ 1,760,455	$ 364,549
Net cash used in operating activities			(5,621,802)	(3,386,634)
Net loss	$ (3,633,020)	$ (2,734,431)	$ (6,634,168)	$ (4,931,748)

Note 3 - Summary of Significa_3

Note 3 - Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Inventory, goods	$ 367,988	$ 357,264
Inventory, parts	283,356	185,691
Inventory, net	$ 651,344	$ 542,955

Note 4 - Accrued Expenses (Deta

Note 4 - Accrued Expenses (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued board of directors' fees	$ 416,667	$ 400,000
Accrued legal and professional fees	200,000	134,970
Accrued executive severance	163,000	154,000
Accrued travel	120,000	120,000
Accrued outside services	106,233	108,033
Accrued inventory	50,275	167,050
Accrued clinical study expenses	13,650	13,650
Accrued other	1,389	13,406
Total accrued expenses	$ 1,071,214	$ 1,111,109

Note 5 - Contract Liabilities_2

Note 5 - Contract Liabilities (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Total contract liabilities	$ 605,537	$ 639,801
Non-current contract liabilities	(53,782)	(573,224)
Current contract liabilities	551,755	66,577
Service Agreement
Total contract liabilities	91,746	133,510
License Fees
Total contract liabilities	500,000	500,000
Other
Total contract liabilities	$ 13,791	$ 6,291

Note 5 - Contract Liabilities_3

Note 5 - Contract Liabilities (Details Narrative) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Contract with Customer, Liability [Abstract]
Remaining performance obligations	$ 551,755	$ 66,577

Note 6 - Short Term Notes Pay_2

Note 6 - Short Term Notes Payable (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020
Notes Payable [Abstract]
Conversion of short term notes and convertible notes payable	$ 90,745	$ 263,984	$ 180,000	$ 266,667	$ 354,729

Note 9 - Notes Payable, Relat_2

Note 9 - Notes Payable, Related Parties (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Notes Payable [Abstract]
Notes payable principal	$ 5,372,743		$ 5,372,743		$ 5,372,743
Interest payable, current	2,229,713		2,229,713		$ 1,859,977
Interest expense, related party	$ 187,172	$ 112,984	$ 369,736	$ 332,671

Note 11 - Equity Transactions (

Note 11 - Equity Transactions (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Conversion of short term notes and convertible notes payable	$ 90,745	$ 263,984	$ 180,000	$ 266,667	$ 354,729
Conversion of advances from related parties	16,000	2,098		$ 0	18,098	$ 180,000
Shares issued for services	$ 517,500	$ 200,000
Consulting Agreement
Shares issued for services					$ 287,500

Note 12 - Warrants (Details)

Note 12 - Warrants (Details)	6 Months Ended
	Jun. 30, 2020shares
Warrants outstanding, beginning	9,474,091
Warrants issued	1,000,000
Warrants exercised	(1,000,000)
Warrants expired	(100,000)
Warrants outstanding, ending	9,374,091
Class K Warrants
Warrants outstanding, beginning	7,200,000
Warrants issued	0
Warrants exercised	0
Warrants expired	0
Warrants outstanding, ending	7,200,000
Class O Warrants
Warrants outstanding, beginning	909,091
Warrants issued	0
Warrants exercised	0
Warrants expired	0
Warrants outstanding, ending	909,091
Class P Warrants
Warrants outstanding, beginning	1,365,000
Warrants issued	0
Warrants exercised	(1,000,000)
Warrants expired	(100,000)
Warrants outstanding, ending	265,000

Note 12 - Warrants (Details 1)

Note 12 - Warrants (Details 1)	6 Months Ended
	Jun. 30, 2020$ / shares
Class K Warrants
Warrant exercise price/share	$ .08
Warrant expiration date	June 2025
Class K Warrants
Warrant exercise price/share	$ .11
Warrant expiration date	August 2027
Class O Warrants
Warrant exercise price/share	$ .11
Warrant expiration date	January 2022
Class P Warrants
Warrant exercise price/share	$ .20
Warrant expiration date	June 2024
Common Stock Purchase Warrants
Warrant exercise price/share	$ .35
Warrant expiration date	June 2025

Note 13 - Commitments and Con_3

Note 13 - Commitments and Contingencies (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Right of use assets	$ 243,251	$ 323,661
Lease liability - right of use, current	173,270
Lease liability - right of use, noncurrent	99,142
Lease liability - right of use	$ 272,412

Note 13 - Commitments and Con_4

Note 13 - Commitments and Contingencies (Details 1)	Jun. 30, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
2020 (remainder)	$ 97,041
2021	197,462
Total lease payments	294,503
Less: imputed interest	(22,090)
Total operating lease liability	$ 272,412

Note 13 - Commitments and Con_5

Note 13 - Commitments and Contingencies (Details 2) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Right of use assets	$ 515,551
Lease liability - right of use, current	181,371	$ 121,634
Lease liability - right of use, noncurrent	333,771	$ 271,240
Lease liability - right of use	$ 515,141

Note 13 - Commitments and Con_6

Note 13 - Commitments and Contingencies (Details 3)	Jun. 30, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
2020 (remainder)	$ 117,297
2021	234,593
2022	199,793
2023	18,388
Total	$ 570,071

Note 13 - Commitments and Con_7

Note 13 - Commitments and Contingencies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Weighted average remaining lease term, operating lease	1 year 6 months		1 year 6 months
Weighted average discount rate, operating lease	7.00%		7.00%
Rent expense	$ 52,346	$ 54,698	$ 117,876	$ 107,536
Weighted average remaining lease term, finance lease	2 years 5 months 8 days		2 years 5 months 8 days
Weighted average discount rate, finance lease	13.20%		13.20%

Note 14 - Revenue (Details)

Note 14 - Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenues	$ 83,301	$ 316,976	$ 231,893	$ 494,939
Product
Revenues	69,341	220,667	143,900	285,232
License Fees
Revenues	0	66,808	10,000	173,058
Other
Revenues	13,960	29,501	77,993	36,649
United States
Revenues	63,787	126,738	107,982	150,667
United States | Product
Revenues	63,076	120,488	96,730	138,167
United States | License Fees
Revenues	0	6,250	10,000	12,500
United States | Other
Revenues	711	0	1,252	0
International
Revenues	19,514	190,238	123,911	344,272
International | Product
Revenues	6,265	100,179	47,170	147,065
International | License Fees
Revenues	0	60,558	0	160,558
International | Other
Revenues	$ 13,249	$ 29,501	$ 76,741	$ 36,649

Note 14 - Revenue (Details Narr

Note 14 - Revenue (Details Narrative)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Distributor 1 | Revenue
Concentration risk	86.00%
Distributor 1 | Accounts Receivable
Concentration risk	72.00%	49.00%
Three Distributors | Revenue
Concentration risk		72.00%
Distributor 2 | Accounts Receivable
Concentration risk		0.00%
Distributor 3 | Accounts Receivable
Concentration risk		25.00%

Note 15 - Related Party Tran_2

Note 15 - Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Contract liabilities	$ 605,537		$ 605,537		$ 639,801
A. Michael Stolarski
Revenues from related party	13,105	$ 17,678	26,210	$ 138,167
Contract liabilities	$ 90,943	$ 102,899	$ 90,943	$ 102,899

Note 16 - Stock-based Compens_2

Note 16 - Stock-based Compensation (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Dec. 31, 2019
Share-based Payment Arrangement, Noncash Expense [Abstract]
Stock-based compensation	$ 44,250	$ 31,758
Exercise prices for options, lower range limit			$ .04	$ 0.04
Exercise prices for options, upper range limit			$ 2	$ 2
Aggregate intrinsic value for vested and exercisable options	$ 3,034,841		$ 3,034,841	$ 2,085,866
Weighted average remaining contractual term for outstanding exercisable stock options			6 years 1 month 6 days	6 years 7 months 6 days

Note 17 - Earnings (Loss) Per_3

Note 17 - Earnings (Loss) Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Anti-dilutive securities	68,519,676	126,545,367
Stock Options
Anti-dilutive securities	34,168,385	32,183,385
Preferred Stock Conversion
Anti-dilutive securities	17,500,000	0
Warrants
Anti-dilutive securities	9,374,091	68,357,635
Convertible Promissory Notes
Anti-dilutive securities	5,227,200	26,004,347
Short Term Notes Payable
Anti-dilutive securities	2,250,000	0